Louisiana Clinical Trials Report — May 2026

For Louisiana residents considering participation in clinical research, May 2026 brings a significant opportunity to contribute to a major global study, even as the overall number of new trials opening this month is lower than usual. A prominent Phase 3 drug trial from Novo Nordisk A/S is now recruiting across several Louisiana cities, focusing on individuals with specific heart conditions and obesity. This trial represents a chance to engage with cutting-edge research from a leading pharmaceutical sponsor.

At the same time, a critical window is closing for many other studies. Across Louisiana, 52 clinical trials are slated to conclude enrollment within the next 90 days. This includes 9 trials that are actively seeking healthy volunteers, offering a chance for individuals without specific health conditions to participate before these opportunities vanish. Those interested in contributing to medical advancements, whether as a patient or a healthy volunteer, should explore these options promptly.

A Landmark Study Arrives in Louisiana

This month, the most notable new research initiative in Louisiana is a substantial Phase 3 drug trial sponsored by Novo Nordisk A/S. This study, NCT07567001, is titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." It aims to enroll a large global cohort of 5,610 participants, evaluating the safety and effectiveness of the investigational drug NNC0487-0111.

This trial is specifically designed for individuals living with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF), who also have excess body weight. It represents a significant effort to address complex health challenges that often coexist, offering a potential new treatment pathway for these conditions. The study is an industry-sponsored initiative, underscoring the commitment of major pharmaceutical companies to advancing medical science in Louisiana.

A Quiet Month for New Research, But Opportunities Remain

While the Novo Nordisk trial is a significant addition, May 2026 has seen a notable decrease in the overall number of new clinical trials opening in Louisiana. Only 1 new trial launched this month, a sharp contrast to the 10 new trials that opened in April 2026 and 9 in March 2026. This trend marks the lowest number of new openings in the past six months, with the previous low being 7 new trials in January 2026.

Despite this dip in new openings, Louisiana continues to host a robust research environment. Currently, there are 849 clinical trials actively recruiting participants across 49 cities and 645 research sites statewide. This broad distribution ensures that research opportunities are accessible to many residents, even if the pace of new trial launches has slowed.

The single new trial this month is a drug trial, and it includes older adults among its eligible participants. No new trials this month are specifically for children, or exclusively for male or female participants.

Geographic Spread of Research Opportunities

Even with only one new trial opening this month, its recruitment sites are spread across multiple cities, demonstrating a commitment to making research accessible beyond the largest metropolitan areas. The Novo Nordisk study, NCT07567001, is recruiting in:

• Bossier City
• Eunice
• Houma
• Opelousas
• Shreveport

This distribution ensures that residents in various parts of Louisiana have the opportunity to participate in this important Phase 3 study, addressing conditions like heart failure and obesity.

Act Now: Trials Closing Soon

The urgency to participate is particularly high for the 52 trials that will close their enrollment within the next 90 days. These studies cover a diverse range of health conditions, and for many, this is the last chance to join. Among these are 9 trials that are specifically looking for healthy volunteers, providing a valuable pathway for individuals to contribute to medical research without having a diagnosed condition.

Conditions with trials nearing their enrollment deadlines include:

• Acute gouty arthritis
• Acute limb ischemia
• Advance care planning
• Advance directives
• Advanced breast cancer
• AHRF (Acute Hypoxemic Respiratory Failure)
• Anatomic Stage II breast cancer AJCC v8
• Anatomic Stage III breast cancer AJCC v8
• ARDS (Moderate or Severe)
• Ascites hepatic

If you or someone you know is affected by these conditions, or if you are a healthy volunteer interested in contributing, it is crucial to investigate these opportunities quickly before they are no longer available.

Healthy Volunteers and Broader Participation

While the single new trial this month does not accept healthy volunteers, there are still ample opportunities across Louisiana for those without specific medical conditions. A total of 86 clinical trials statewide are currently recruiting healthy volunteers. These trials play a vital role in establishing baseline data and testing new interventions, and your participation can be invaluable.

For those interested in the new Novo Nordisk trial, it is important to note that it includes older adults in its eligibility criteria, ensuring that this demographic has a chance to participate in this significant heart failure and obesity study. Individuals interested in any clinical trial should always carefully review the specific eligibility requirements to determine if they qualify.

As we move further into May, the focus will be on the continued enrollment in the significant Novo Nordisk trial and the rapid conclusion of many other studies. Louisiana's research landscape remains dynamic, offering diverse opportunities for those ready to contribute to the future of medicine.